Earlier on Friday, 29 May, I shared with you news of the above mentioned collaboration but what is the significance of it?
A poster on ihub who works in the pharmaceutical industry, shared with the readers his insights:
1) MSK has deep ties with Bristol Myers Squibb (BMY) that goes beyond the normal clinical trial management and execution. It has access to top management level with regards to product development strategy and opportunities.
2) MSK has deep knowledge of BMY products.
3) MSK has been building a Cancer Immunology "Dream Team" since 2012.
4) MSK has been on the lookout for products can could create multiple pathways for the treatment of cancer
My opinion? Normally a reputed research centre such as MSK works behind the scenes and very seldomly would make an announcement identifying other parties or their drugs unless they are of major significance. Therefore Bavituximab and PS-targeting must be of great importance to MSK in their continual search for the best cancer immunotherapy treatment which can align with BMY objectives.
This invariably puts the pressure on the other Big Pharma like Pfizer, Roche, Abbvie, Merck etc, on the defensive and makes them wonder if PPHM could provide what they desperate need to improve their own drugs efficacy and safety.
Definitely, PPHM is on the threshold of something big. At US$1.41 it is a screaming BUY.
My disclosure: I am long PPHM.
Still, always do your own research and investing is a pharma start up carries with it some high risks. It is up to you to determine the risk to reward ratio.
No comments:
Post a Comment